Prescient Therapeutics (PTX) is looking to raise $8 million via a share purchase plan (SPP) to progress its PTX-100 and PTX-200 cancer treatment therapies.
The company said it would also use the funds to progress its cell therapies to first-in-human clinical studies and for general working capital.
Under the SPP, shareholders will be able to subscribe for $30,000 worth of new shares at 17.5 cents per share. This price represents a 14.6 per cent discount to Prescient’s volume-weighted average price over the five trading days before August 24.
Prescient CEO and Managing Director Steven Yatomi-Clarke said the company was seeking to maintain its momentum of “incredible” growth and its position at the forefront of oncology innovation.
“Prescient continues to build out a diverse and innovative pipeline of personalised therapies for cancer,” Mr Yatomi-Clarke said.
The SPP is anticipated to close on September 29, with results to be announced on October 3 and shares issued on October 5.
Last week, Prescient signed a deal with Thermo Fisher Scientific to accelerate the development of its OmniCar platform.
Under the agreement, a development will be constructed to evaluate the potential of using automated, closed cell therapy solutions to develop a novel process of manufacturing cell therapies on the OmniCAR platform using non-viral methods.
Shares in Prescient Therapeutics were down 14.3 per cent and trading at 18 cents at 2:51 pm AEST.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.